Zhengda Qingjiang's anti-inflammatory drug "celecoxib capsule" passed consistency evaluation

Release date: 2020-01-10 Views: 0

Source: Minnet  

On January 9, China Biopharmaceutical issued an announcement saying that its subsidiary, Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., has developed a drug registration certificate for the treatment of arthritis, Celecoxib Capsule. This product is the second one of its kind in China to be approved and is deemed to have passed the consistency evaluation.

It is reported that celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor nonsteroidal anti-inflammatory drug, which is used to alleviate the symptoms and signs of osteoarthritis and alleviate the symptoms of human rheumatoid arthritis And signs, treatment of acute pain in adults, etc.

Sales of celecoxib capsules in Chinese public medical institutions (Unit: 10,000 yuan)

According to, the sales of terminal celecoxib capsules in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) exceeded 1 billion yuan in 2018, a year-on-year increase of 25.28%.

Before that, the manufacturers were Pfizer and Hengrui. China Biopharmaceutical said that the approval of celecoxib capsules will further enrich the Group's product portfolio and help the Group's development in the field of orthopedic medicine.

In terms of consistency evaluation, both Hengrui and Zhengda Qingjiang were approved as imitation 4 types of applications, which are deemed to have passed the consistency evaluation.

Source: Announcement of Listed Company, Minnet Database

recommended article

Hunter QR code